Printer Friendly

ALK immunocytochemistry can detect ALK-rearranged NSCLC on cytological specimens, study shows.

M2 PHARMA-July 3, 2013-ALK immunocytochemistry can detect ALK-rearranged NSCLC on cytological specimens, study shows(C)2013 M2 COMMUNICATIONS

3 July 2013 - A study has shown that anaplastic lymphoma kinase (ALK) immunocytochemistry is highly accurate in the detection of ALK-rearranged non-small cell lung cancer (NSCLC) on cytological specimens, US-based International Association for the Study of Lung Cancer (IASLC) said earlier this week.

The study retrospectively analysed 41 specimens with available ALK fluorescence in situ hybridisation (FISH) results with the 5A4 monoclonal antibody (mAb) on a fully automated slide stained. The study population was enriched for consecutive ALK FISH-positive NSCLCs. The research also comprised 18 consecutive ALK FISH-negative NSCLCs with EGFR and KRAS wild-type as negative controls.

According to the results, the sensitivity, specificity and positive and negative predictive values for ALK immunocytochemistry versus ALK FISH were 93.3%, 96%, 93.3% and 96%, respectively.

The findings show that cytological NSCLC specimens are suited for ALK rearrangement testing and that ALK ICC with the 5A4 mAb is feasible and highly accurate in detecting ALK-rearranged NSCLC on conventional cytological specimens and cellblock preparations.

((Comments on this story may be sent to

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 3, 2013
Previous Article:Analytik Jena unit gets regulatory approval for 2 ELISA-based tests for PRRSV.
Next Article:GeneNews' newly set up JV to launch accredited clinical lab in USA.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters